Abstract Dysregulation of cyclin-dependent kinase 4/6 (CDK4/6) occurs in cancer and is targeted by CDK4/6 inhibitors (CDK4/6i) including palbociclib (PD). CDK4/6i triggers quiescence (reversible) which transitions to senescence (irreversible) following prolonged exposure. Resolving the program that directs this transition is critical to overcoming CDK4/6i resistance and improving the efficacy of CDK4/6 inhibitors.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile